PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH...

PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

Fioratti, C., Rachid, M.L., Baida, R., Decimoni, T., Brunelli, M.J.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.1135
Date:
November, 2019
File:
PDF, 381 KB
2019
Conversion to is in progress
Conversion to is failed